The expanded B cell clones from the TRAF3xBCL2-tg+/+ mice that have developed post-germinal center (GC) NHL malignancies used more frequently genes from the IGHV1 subgroup genes (56%), similar to the Traf2DNxBCL2-tg+/+ CLL/SLL clones, but the usage of IGHV5 (12.5%) and IGHV14 (6.3%) genes is much reduced compared to the latter. This evidence concerns the gene TG and non-Hodgkin lymphoma.